Forest As An Aggressive In-Licenser
A steady stream of dealmaking in recent years, primarily small, in-licensing transactions to build pipeline and portfolio, transformed Forest under the leadership of longtime CEO Howard Solomon. The activity was driven in large part by the anticipated, huge 2012 patent cliff, but it was far from enough.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.